Certa Therapeutics announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis, having previously granted Orphan Drug Designation.
Certa Therapeutics announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis, having previously granted Orphan Drug Designation.